fund
Schroder Global Healthcare Z
Global healthcare and medical services companies.
-
219.00p
Price (Inc)
These are the shares in the fund that pay out an income to clients. The income is made up of the total dividends – the money a company can pay out to its investors – from the companies in the fund.
-
230.30p
Price (Acc)
These are the shares in the fund that don’t pay out an income to clients. Any dividends – the money a company can pay out to its investors – are reinvested into companies in the fund. Despite no income, the shares should be worth more over time. Good incentive, eh?
-
0.00%
Initial chargeSome funds charge you when you first invest, which is aptly known as the initial charge. They’re usually between 3-5% but at Bestinvest, we usually don’t charge you a penny!
-
0.75%
Annual management charge
This is how much the fund management company charges to run the fund. It’s like paying a babysitter, dog sitter or house sitter (that makes well-informed, heavily researched changes to improve your baby/dog/house when needed).
-
0.93%
Ongoing charges
This stands for Ongoing Charges Figure. It’s the cost of running a fund and includes admin fees, manager fees, administration costs, etc.
-
0.20%
Yield
How much the fund is currently paying out in income to investors. It’s NOT to be confused with the overall growth of a fund – a very different thing indeed. It’s also NOT a guarantee of future pay-outs, just a snapshot. This is more what it’s not than what it is…
The fund's investment objective is to achieve capital growth. The fund will invest in healthcare, medical services and related products and companies on a worldwide basis.
Fund summary
| Sector | Global |
| Structure | UNIT TRUST |
| Launched | November, 2011 |
| Size | £429m |
| Yield | 0.20% |
| Charging basis | Income |
| Dividends paid | 15 Jan |
Charges
| Standard initial charge | 0.00% |
| Initial charge via Bestinvest | 0.00% |
| Additional bid/offer spread | 0.00% |
| Annual management charge | 0.75% |
| Ongoing charges figure | 0.93% |
Allocation
Proportion (%)
-
{{chartDataItem.text}}{{chartDataItem.value}}
Allocation
Proportion (%)
-
{{chartDataItem.text}}{{chartDataItem.value}}
Allocation
Proportion (%)
-
{{chartDataItem.text}}{{chartDataItem.value}}
Investment process
Manager research
Average monthly relative returns
- 16/17 -0.88%
- 17/18 -0.13%
- 18/19 -0.12%
- 19/20 0.22%
- 20/21 0.90%
Bestinvest MRI
- 3 years 0.33%
- 5 years 0.00%
- Career -0.03%
- 3 years 94.70%
- 5 years 63.70%
- Career 67.70%
Performance figures are based on the average of monthly percentage returns relative to the benchmark index.
John Bowler
John has ten years of investment experience. He studied at university to earn degrees in Biology, PhD Biochemistry & Physiology. Prior to joining Axa in 1998, he worked as a healthcare analyst at State Street Research & Management and Hill Samuel Asset Management. He also has a degree in Biology and a PhD in Biochemistry and Physiology. John was a key investor on the AXA Healthcare Fund from mid 2001 to December 2002, with a primary responsibility for recommending stocks for selection. John joined Schroders in 2003 and is currently global sector leader for healthcare research with specific stock coverage including Pan-European Pharmaceuticals and US Medical Device companies. He has obtained the ASIP and now is a director.
Track record
John Bowler has 16.8 years experience of managing mutual funds in this sector. Over this period the average monthly return relative to the benchmark index has been -0.03%. During the worst period of relative performance (from August 2004 - December 2018) there was a decline of 25% relative to the index. The worst absolute loss has been 14%.
Periods of worst performance
| Absolute | -14.00% (March 2010 - July 2010) |
| Relative | -25.00% (August 2004 - December 2018) |
About the MRI
Our unique indicator: the Bestinvest Manager Record Index (MRI) measures the likelihood that the fund manager is adding value through their decisions. It is based on their performance record over the course of their career, adjusted for the amount of risk taken. MRI is an important contributor to our fund rating system but it is also vital to take account of qualitative factors. It is also very important to select funds to form a cohesive portfolio with an appropriate overall risk level.
Allocation
Proportion (%)
-
{{chartDataItem.text}}{{chartDataItem.value}}
Allocation
Proportion (%)
-
{{chartDataItem.text}}{{chartDataItem.value}}
Allocation
Proportion (%)
-
{{chartDataItem.text}}{{chartDataItem.value}}
Top 10 holdings
Data accurate as at 31 July 2020
| 5.66% | Unitedhealth Group Inc |
| 4.52% | Roche Hldg Ag |
| 4.15% | Thermo Fisher Scientific Inc |
| 4.11% | Abbott Laboratories |
| 3.51% | Amgen Inc |
| 3.33% | Novartis Ag |
| 3.25% | Sanofi |
| 3.15% | Bristol Myers Squibb Sa |
| 2.78% | Merck & Co Inc(New) |
| 2.35% | Anthem Inc |
| Source: Trustnet |
Sector breakdown
| Health Care | 95.00% |
| Money Market | 4.00% |
| Industrials | 1.00% |